Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TISSUE TESTING TECHNOLOGIES LLC
- Proposal award date
- 2019-09-11
- Contract end date
- 2021-08-31
- UEI
- ZSY2J1RRALT5
- Solicitation number
- PA18-574
- Topic code
- NIAMS
Research abstract
Resurfacing of articular cartilage with cold stored osteochondral allografts is employed clinically for repair of
trauma and osteoarthritis-induced articular cartilage surface damage. Chondrocyte viability of transplanted
articular cartilage is accepted as one of the determinants of outcome following osteochondral allograft
transplantation. We have previously developed an ice-free vitrification method of cryopreservation that
maintains excellent chondrocyte viability in animal model and human articular cartilage. The chondrocytes
survive vitrification due to the absence of ice formation during cooling and warming of 1-3mL samples.
However, it had not been possible to rewarm larger samples due to ice nucleation during rewarming that
results in loss of chondrocyte viability prior to our Phase I studies. The innovation in this proposal relates to a
new rewarming method that does not have the limitations of boundary convection warming that should be
effective for samples up to 50mL in volume. This rewarming method utilizes radio frequency induced heating of
magnetic iron nanoparticles. In Phase I we demonstrated the effectiveness of ice-free vitrification combined
with nanowarming for large full thickness osteochondral tissues in 50 mL volumes in 80 seconds with
maintenance of both chondrocyte viability and extracellular matrix integrity. In Phase II we propose
development of a porcine model, further optimization of ice-free vitrification and nanowarming and in vivo
evaluation in a porcine model in three specific aims. Nanowarmed chondrocyte viability, chemistry, and
biomaterial properties will be compared with untreated fresh control tissues both before and after transplant.
The nanowarming conditions that provides the best preservation of chondrocytes with minimal if any cartilage
biomaterial changes will be selected for further investigation and translation to human cartilage in a
subsequent Phase IIb SBIR application.Both literature review and an independent survey indicate that there is a significant need for a cartilage
preservation solution for clinical and research applications that maintains both chondrocyte viability and
cartilage biomaterial properties. The impact of this research will be optimized preservation of both articular
cartilage chondrocytes and biomaterial properties making transplants more effective in vivo. Commercialization
of this cartilage storage technology will result in increased utilization of banked allogeneic cartilage for
reconstruction of articular cartilage defects in patients. The cryopreservation formulation and magnetic iron
particles will also be commercialized for cartilage storage for research and future tissue engineered cartilage
products.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
22 SBIR/STTR records share this UEI (2014–2023). Reported award amounts total $9,665,888. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards